Literature DB >> 26105129

The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010.

Mary Nguyen-Nielsen1, Lisa Wang2, Lars Pedersen1, Anne Braae Olesen3, Jeannie Hou2, Howard Mackey2, Margaret McCusker2, Nicole Basset-Seguin4, Jon Fryzek5, Mogens Vyberg6.   

Abstract

BACKGROUND: Few data exist on the occurrence of metastatic basal cell carcinoma (mBCC).
OBJECTIVE: To identify all cases of mBCC in Denmark over a 14-year period.
METHODS: We searched the Danish National Patient Registry covering all Danish hospitals, the Danish Cancer Registry, the National Pathology Registry and the Causes of Death Registry during the period 1997 to 2010 for potential cases of mBCC registered according to the International classification of diseases ICD-10 and the International Systemized Nomenclature of Medicine (SNOMED).
RESULTS: We identified 126,627 patients with a history of primary basal cell carcinoma (BCC) in the registries during the 14-year study period. Using case identifications from the four registries, a total of 170 potential mBCC cases were identified. However, after a pathology review, only five cases could be confirmed, of which three were basosquamous carcinomas. The 14-year cumulative incidence proportion of mBCC was 0.0039% (95% CI 0.0016-0.0083) among individuals with a history of previous BCC (n = 126,627) and 0.0001% (95% CI 0.0000-0.0002) in the general population.
CONCLUSION: MBCC is a rare disease and only a small proportion of potential cases identified in automated clinical databases or registries can be confirmed by pathology and medical record review.

Entities:  

Keywords:  basal cell carcinoma; epidemiology; incidence; metastases

Mesh:

Year:  2015        PMID: 26105129     DOI: 10.1684/ejd.2015.2546

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  7 in total

1.  The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.

Authors:  James Randall Patrinely; Anna K Dewan; Douglas B Johnson
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

2.  Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

Authors:  Gino Kim In; Aparna Nallagangula; Jacob Seung Choi; Lisa Tachiki; Matthew J Blackburn; Stephen Capone; Kathryn B Bollin; Daniel Y Reuben; Keisuke Shirai; Sandy Zhang-Nunes; Omar Ragab; Alicia Terando; Jenny C Hu; Han Lee; Shailender Bhatia; Sunandana Chandra; Jose Lutzky; Geoffrey Thomas Gibney
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

3.  Detecting recurrent head and neck cancer using electronic nose technology: A feasibility study.

Authors:  Rens M G E van de Goor; Joey C A Hardy; Michel R A van Hooren; Bernd Kremer; Kenneth W Kross
Journal:  Head Neck       Date:  2019-04-23       Impact factor: 3.147

4.  Metastatic Basal Cell Carcinoma: Case Report and Review of the Literature.

Authors:  José-Francisco Millán-Cayetano; Nuria Blázquez-Sánchez; Inés Fernández-Canedo; Juan Bosco Repiso-Jiménez; Rafael Fúnez-Liébana; María Dolores Bautista; Magdalena de Troya-Martin
Journal:  Indian J Dermatol       Date:  2020 Jan-Feb       Impact factor: 1.494

Review 5.  Imaging findings of malignant skin tumors: radiological-pathological correlation.

Authors:  Masaya Kawaguchi; Hiroki Kato; Yoshifumi Noda; Kazuhiro Kobayashi; Tatsuhiko Miyazaki; Fuminori Hyodo; Masayuki Matsuo
Journal:  Insights Imaging       Date:  2022-03-22

6.  Ulcerated Metatypical Basal Cell Carcinoma of the Forehead.

Authors:  Jose Cardoso; Uwe Wollina; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2017-10-03

7.  Magnetic Resonance Imaging Findings Differentiating Cutaneous Basal Cell Carcinoma from Squamous Cell Carcinoma in the Head and Neck Region.

Authors:  Masaya Kawaguchi; Hiroki Kato; Hiroyuki Tomita; Akira Hara; Natsuko Suzui; Tatsuhiko Miyazaki; Kanako Matsuyama; Mariko Seishima; Masayuki Matsuo
Journal:  Korean J Radiol       Date:  2020-03       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.